title: Left behind? Drug discovery in extensive-stage small-cell lung cancer.
abstract: Systemic therapy and subsequent survival for patients with extensive-stage small-cell lung cancer (SCLC) are poor and have remained unchanged in the past quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instead focuses on tumor biology and heterogeneity as a means to increase target and drug class diversity. By incorporating tools that have led to new diagnostic and treatment options in non-small-cell lung cancer, there could be hope yet for the future of SCLC therapeutics.
authors: University of California Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address: jonathan.riess@ucdmc.ucdavis.edu.
authors: Jonathan W
authors: JW
authors: Riess
authors: University of California Davis School of Medicine and UC Davis Comprehensive Cancer Center, Sacramento, CA.
authors: Primo N
authors: PN
authors: Lara
mesh_terms: D055808:Drug Discovery; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D055752:Small Cell Lung Carcinoma / Q000473:pathology / Q000628:therapy*
keywords: Amrubicin; Chemotherapy; Clinical trials; Developmental therapeutics; Small cell lung cancer